Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
Newsable Asianet News on MSN21h
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders RejoiceShares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street. Canaccord initiated coverage on the stock with a ...
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback